4D Molecular Therapeutics (FDMT) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed 4D Molecular Therapeutics (FDMT) over the past year, gaining 166.3% versus a gain of 31.5%. Over five years, OABI leads with a -53.3% price change compared with -53.5% for FDMT. 4D Molecular Therapeutics is the larger company by market cap ($701.6 million vs $677.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | OABI |
|---|---|---|
| Share price | $12.70 | $4.66 |
| Market cap | $701.60M | $677.52M |
| 1-day change | +0.87% | +2.19% |
| YTD return | +69.33% | +151.89% |
| 1-year return | +31.47% | +166.29% |
| 5-year return | -53.51% | -53.26% |
| EPS (TTM) | $-2.63 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $5.43 |
| 52-week low | $6.96 | $1.30 |
| Distance from 52-week high | -24.99% | -14.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.18% | +78.76% |
| Average volume | 926.78K | 1.47M |
| Shares outstanding | 55.24M | 145.39M |
| Employees | 196 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed FDMT by 134.8 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
FDMT vs OABI FAQ
Which is bigger, 4D Molecular Therapeutics or OmniAb?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $701.60M compared with $677.52M for OmniAb (OABI).
Which stock has performed better over the past year, FDMT or OABI?
OABI returned +166.29% over the past 12 months, compared with +31.47% for FDMT (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for 4D Molecular Therapeutics and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.